New Jersey Administrative Code › Title 13 - LAW AND PUBLIC SAFETY › Chapter 45A - ADMINISTRATIVE RULES OF THE DIVISION OF CONSUMER AFFAIRS › Subchapter 35 - PRESCRIPTION MONITORING PROGRAM › Section 13:45A-35.6 - Access to prescription monitoring information; retention of information

Current through Register Vol. 56, No. 14, July 15, 2024
(a) The Division shall provide online access to prescription monitoring information submitted to the PMP to the following:
1. A pharmacist who is employed by a current pharmacy permit holder and is authorized to dispense controlled dangerous substances, human growth hormone, or gabapentin who certifies that the request is for the purpose of providing health care to or verifying information with respect to a new or current patient, or verifying information with respect to a prescriber;
2. A practitioner who has a current CDS registration and is authorized to prescribe, dispense, or administer controlled dangerous substances, human growth hormone, or gabapentin who certifies that the request is for the purpose of providing health care to or verifying information with respect to a new or current patient of the practitioner, or verifying information with respect to a prescriber;
3. A delegate authorized by a practitioner to access the PMP information for the purpose of providing health care to a new or current patient of the delegating practitioner who certifies that the request is for the purpose of providing health care to or verifying information with respect to a new or current patient of the delegating practitioner, or verifying information with respect to a prescriber, consistent with the requirements of this subchapter;
4. A current medical resident of a medical teaching facility who is authorized to access PMP information and who certifies that the request is for the purpose of providing health care to or verifying information with respect to a new or current patient at the medical teaching facility for whom the residency program has responsibility of care, or verifying information with respect to a prescriber, consistent with the requirements of this subchapter;
5. A current dental resident of a dental teaching facility who is authorized to access PMP information and who certifies that the request is for the purpose of providing health care to or verifying information with respect to a new or current patient at the medical teaching facility for whom the residency program has responsibility of care, or verifying information with respect to a prescriber, consistent with the requirements of this subchapter;
6. A designated representative of the State Board of Medical Examiners, New Jersey State Board of Dentistry, New Jersey Board of Nursing, New Jersey State Board of Optometrists, New Jersey State Board of Pharmacy, State Board of Veterinary Medical Examiners, or any other board in this State or another state that regulates the practice of persons who are authorized to prescribe or dispense controlled dangerous substances, human growth hormone, or gabapentin, as applicable, who certifies that he or she is engaged in a bona fide specific investigation of a designated practitioner whose professional practice was or is regulated by that board;
7. A designated representative of a state Medicaid or other government program who certifies that he or she is engaged in a bona fide investigation of a designated practitioner, pharmacist, or patient;
8. The State Medical Examiner, a county medical examiner, a deputy or assistant county medical examiner, or a qualified designated assistant thereof, who certifies that the request Is for the purpose of Investigating a death pursuant to P.L 1967, c. 234 (N.J.S.A. 52:17B-78et seq.);
9. Effective after 30 days public notice in the New Jersey Register, a licensed mental health practitioner providing treatment for substance abuse to patients at a residential or outpatient substance abuse treatment center licensed by the Department of Health provided that the licensed mental health practitioner:
i. Certifies that the request Is for the purpose of providing health care to a current patient at a residential or outpatient substance abuse treatment center licensed by the Department of Health, or verifying Information with respect to a patient or practitioner; and .
ii. Provides the Division with the written consent of the patient for the mental health practitioner to obtain prescription monitoring Information about the patient.
(1) Patient consent shall be valid for the period of treatment by the mental health practitioner at the residential or outpatient substance abuse treatment center or for one year. whichever is less. After one year, the mental health practitioner shall re-obtain, and re-submit to the Division, the written consent of the patient; and.
10. Authorized personnel, as determined by the Director of the Division, responsible for administration of the provisions of P.L 1970, c. 226 (N.J.S. A. 24:21-1 etseq.).